CHOP and DHAP plus rituximab followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): a phase II study from the GELA.
Blood. 2012 Jun 20
Anskar Leung
01 Aug 2012
|
Clinical Trial
Mantle cell lymphoma (MCL) constitutes 5-10% of all cases of lymphoma. The median age of onset is about 60 and the clinical course is generally aggressive, with most patients presenting with advanced diseases. Conventional treatment as is used for diffuse large B cell lymphoma, i.e. a combination of rituximab, cyclophosphamide, oncovin...
INDIVIDUAL SUBSCRIPTIONS
Get instant access to Article Recommendations from more than 5,000 expert scientists and clinical researchers, assisted by 5,000 associates, by taking out a monthly subscription. The first month of your subscription will be free of charge.
Start your personal subscription today.
Subscribe for $9.95/monthINSTITUTIONAL SUBSCRIPTIONS
Send a recommendation to your institution's librarian or information manager to request an extended free trial for all users.
Recommend to your LibrarianIf you are a librarian or information manager, you may request an extended free trial for your academic or corporate institution.
Request an Institutional Trialyour institution might be eligible for free access via our sponsorship scheme. Check our sponsorship page.
If you think you should be able to access this content, please contact us.